Physician profile
Sofia M Ramirez
NPI 1104504703
$9,302.88
in general payments reported to CMS, 2019-2025
62 companies · $5,225 in 2025
The $5,225 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $4,078 · 2025: $5,225.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,824 · Education: $479.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,823.93 |
| Education | $478.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $951.96 | 2024-2025 | Enhertu, Lynparza, Imfinzi |
| Janssen Biotech, INC. | $845.07 | 2024-2025 | Rybrevant, Darzalex, Erleada |
| Novartis Pharmaceuticals Corporation | $779.69 | 2024-2025 | |
| Incyte Corporation | $500.91 | 2024-2025 | Jakafi, Monjuvi, Zynyz |
| Sobi, INC | $445.38 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $437.97 | 2024-2025 | Keytruda, Welireg, Lynparza |
| Pfizer INC. | $383.11 | 2024-2025 | |
| Eisai INC. | $333.69 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $323.62 | 2024-2025 | |
| Celgene Corporation | $319.56 | 2024-2025 | Reblozyl |
| Astellas Pharma US INC | $300.41 | 2024-2025 | Vyloy, Xtandi, Padcev |
| Daiichi Sankyo INC. | $222.97 | 2024-2025 | Enhertu, Vanflyta |
| Abbvie INC. | $211.59 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $193.22 | 2024-2025 | Ninlaro, Fruzaqla, Iclusig |
| Genzyme Corporation | $175.68 | 2024-2025 |
Show all 62 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmaessentia USA Corporation | $159.19 | 2024-2025 | Besremi |
| Geron Corporation | $155.37 | 2025 | Rytelo |
| Alexion Pharmaceuticals, INC. | $131.53 | 2024-2025 | Ultomiris |
| Gilead Sciences, INC. | $126.39 | 2024-2025 | Trodelvy |
| Genentech USA, INC. | $119.59 | 2024-2025 | Polivy, Venclexta, Phesgo |
| Glaxosmithkline, LLC. | $109.97 | 2024-2025 | Ojjaara, Jemperli, Zejula |
| Ipsen Biopharmaceuticals, INC | $99.99 | 2025 | |
| Lilly USA, LLC | $99.68 | 2024 | Jaypirca, Verzenio, Retevmo |
| Syndax Pharmaceuticals, INC. | $98.76 | 2025 | |
| Stemline Therapeutics INC. | $97.77 | 2024-2025 | Orserdu |
| Array Biopharma INC | $96.68 | 2024-2025 | Mektovi, Braftovi, Lorbrena |
| Karyopharm Therapeutics INC. | $83.84 | 2024-2025 | Xpovio |
| Emd Serono, INC. | $82.91 | 2025 | |
| Tersera Therapeutics LLC | $82.02 | 2024-2025 | Zoladex |
| Servier Pharmaceuticals LLC | $79.11 | 2024-2025 | |
| Deciphera Pharmaceuticals INC. | $68.97 | 2024-2025 | Qinlock, Romvimza |
| Menarini Silicon Biosystems, INC. | $64.69 | 2024-2025 | |
| Fennec Pharmaceuticals, INC. | $64.47 | 2024-2025 | Fyarro, Pedmark |
| Beone Medicines USA, INC. | $62.78 | 2025 | Brukinsa |
| Regeneron Healthcare Solutions, INC. | $62.23 | 2024-2025 | Libtayo |
| Jazz Pharmaceuticals INC. | $61.78 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $59.54 | 2025 | Opdivo |
| Recordati_rare_diseases_inc. | $59.41 | 2025 | Enjaymo |
| Adc Therapeutics America, INC. | $59.37 | 2024-2025 | |
| Novocure INC. | $58.90 | 2025 | Optune Lua (Novottf-200t) |
| Tempus Ai, INC | $47.50 | 2024-2025 | Xt Cdx |
| Exelixis INC. | $46.54 | 2024-2025 | Cabometyx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.89 | 2025 | |
| Kyowa Kirin, INC. | $45.45 | 2024-2025 | Poteligeo |
| Sanofi-Aventis U.S. LLC | $41.99 | 2024 | |
| Blueprint Medicines Corporation | $41.92 | 2024 | Ayvakit |
| Puma Biotechnology, INC. | $34.03 | 2024-2025 | |
| Immunocore Limited | $31.74 | 2025 | Kimmtrak |
| Iovance Biotherapeutics, INC. | $30.73 | 2025 | Amtagvi |
| Adaptive Biotechnologies Corporation | $30.01 | 2025 | Clonoseq |
| Amneal Pharmaceuticals LLC | $26.31 | 2025 | Alymsys |
| Sun Pharmaceutical Industries INC. | $25.21 | 2024 | |
| Springworks Therapeutics, INC. | $25.16 | 2024 | Ogsiveo |
| Rigel Pharmaceuticals, INC. | $24.40 | 2024 | Rezlidhia, Tavalisse |
| Ucb, INC. | $24.21 | 2024 | Cimzia |
| Dendreon Pharmaceuticals LLC | $18.97 | 2025 | Provenge |
| Coherus Oncology, INC. | $18.50 | 2025 | Loqtorzi |
| Nuvation Bio INC. | $18.48 | 2025 | Ibtrozi |
| Pharmacosmos Therapeutics INC. | $18.42 | 2024 | Cosela |
| Curonix LLC | $16.93 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Agios Pharmaceuticals, INC. | $15.56 | 2025 | Pyrukynd |
| Emmaus Medical, INC. | $5.16 | 2024 | Endari |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sofia Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.